Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol

Vulvovaginal Atrophy Clinical Trial

Official title:

Prospective, Open-label, Multicenter, Multinational, Randomized Trial to Investigate the Non-inferiority of Treatment With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol in a Panel of Post-menopausal Women Suffering From the Symptoms of Vulvovaginal Dryness in a Parallel Group Design

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03044652
• Other study ID #: VFCr-12/2015
• Secondary ID: 2016-002199-28
• Status: Completed
• Phase: Phase 4
• First received: December 21, 2016
• Last updated: July 11, 2017
• Start date: November 2016
• Est. completion date: June 2017

Study information

• Verified date: July 2017
• Source: Dr. August Wolff GmbH & Co. KG Arzneimittel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to gain further experience with regard to the performance of the medical device WO2085 Moisturising Cream in comparison to a cream with 0.1% estriol.

Description:

"Vaginal dryness" is defined as dryness, itching, burning and pain unrelated to sexual intercourse.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 172
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Post-menopausal women with the subjective symptoms of "vulvovaginal dryness" with a sum score (0-16) of the parameters dryness, itching, burning and pain unrelated to sexual intercourse of at least 3 AND a VAS value "Overall impairment of daily life due to the condition "vulvovaginal dryness" > 0 on Visit 1.

• Last menstruation more than 12 months before Visit 1 OR bilateral oophorectomy with or without hysterectomy more than 3 months before Visit 1.

• Physical and mental healthy women as assessed by the medical history.

• PAP test performed within the last 12 months before Visit 1 and result less than PAP III.

• Signed written informed consent before participation in the Trial.

• Willingness to actively participate in the trial and to come to the scheduled visits.

Exclusion Criteria:

• Known hypersensitivity against any of the ingredients of the test products.

• Any indication in the medical history regarding an impairment of the hepatic, renal, gastrointestinal, cardiovascular, pulmonary, endocrinological or hematological system (especially venous and arterial thromboembolism, ischemic stroke, myocardial infarction, porphyria) if clinically relevant for this clinical trial (cf. contraindications and warnings for Estriol cream 0.1%).

• Known thrombophilic disorders (e.g. protein C, protein S or antithrombin deficiency).

• Breast cancer (acute and / or in the medical history or suspected).

• Estrogen-dependent tumor (acute and / or in the medical history or suspected, especially ovarian and / or endometrial carcinoma).

• Systemic hormonal replacement therapy (tablets, patches, injections, dermal products), or phytohormonal therapy or use of SERMs (inter alia anti-estrogens) within 3 months before Visit 1 and / or during the conduct of this trial.

• Intrauterine device (IUD) with progestogen (Mirena®, Jaydess®)

• Pathological findings in cancer screening (Papanicolaou III, III D - V in the cervical test)

• Pathological changes in the vaginal or cervix area, which are caused by estrogen deficiency (except symptoms and condition of "vulvovaginal dryness"), e.g. diminution of labia caused by estrogen deficiency, constricted introitus.

• Patients with known infectious diseases (e.g. hepatitis or HIV infection).

Related Conditions & MeSH terms

• Atrophy
• Vulvovaginal Atrophy

Intervention

Device:
• WO2085 Moisturising Cream
2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).

Drug:
• Estriol Cream 0.1%
0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.

Locations

Country	Name	City	State
Germany	Dr. Gerick	Aachen
Germany	Praxis für die Frau	Mölln
Germany	proDERM Institute for Applied Dermatological Research	Schenefeld
Germany	Praxis für die Frau	Schwarzenbek
Switzerland	Frauenklinik Inselspital Bern	Bern

Sponsors (4)

Lead Sponsor	Collaborator
Dr. August Wolff GmbH & Co. KG Arzneimittel	Bremer Pharmacovigilance Service GmbH, GCP-Service International Ltd. & Co. KG, proDERM Institut für Angewandte Dermatologische Forschung GmbH

Countries where clinical trial is conducted

Germany,  Switzerland, 

References & Publications (4)

Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas. 1995 Dec;22 Suppl:S1-S5. — View Citation

Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010 Jun;26(6):404-12. doi: 10.3109/09513591003632258. — View Citation

Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2. — View Citation

Stute P, May TW, Masur C, Schmidts-Winkler IM. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. Climacteric. 2015;18(4):582-9. doi: 10.3109/13697137.2015.1036854. Epub 2015 May 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Total Severity Score of the Treatment of "vulvovaginal dryness" at 6 weeks.	"Vulvovaginal dryness" will be measured by the Total Severity Score. It is defined as the sum score of the single subjective symptom parameters dryness, itching, burning and pain unrelated to sexual intercourse, each scored from 0=none to 4=very severe. In total a range of 0=no complaints to 16=very severe complaints is possible. Differences to Baseline (Visit 1) of the Total Severity Score assessed after six weeks of treatment (Visit 3) serve as the primary endpoint for the test of non-inferiority.	Baseline, after 3 and 6 weeks
Secondary	Overall impairment of daily life	Overall impairment of daily life due to the condition "vaginal dryness" (including subgroup analysis of patients with mild, moderate or severe impairment) will be measured by using a Visual Analogue Scale (VAS)	6 weeks
Secondary	Global judgement of efficacy	The global judgement of efficacy will be assessed by the investigator and the patient according to the following scale: 1=very good to 4=poor.	6 weeks
Secondary	Global judgement of tolerability	The global judgement of tolerability will be assessed by the investigator and the patient according to the following scale: 1=very good to 4=poor.	6 weeks
Secondary	Adverse Events	Adverse events will be documented on Visits after 3 and 6 weeks, respectively (and in the patient diary, if applicable).	after 3 and 6 weeks